A Phase II study of Ramucirumab beyond disease progression in combination with Irinotecan after failure of weekly Paclitaxel plus Ramucirumab in advanced gastric cancer patients previously treated with fluoropyrimidine and platinum
Latest Information Update: 14 Nov 2022
At a glance
- Drugs Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 13 Nov 2022 Status changed from recruiting to completed.
- 04 Jan 2017 Status changed from not yet recruiting to recruiting.
- 12 Jul 2016 New trial record